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Abstract
Generating an anti-tumor immune response is a multi-step process that is executed by effector T
cells that can recognize and kill tumor targets. However, tumors employ multiple strategies to
attenuate the effectiveness of T cell-mediated attack. This is achieved by interfering with nearly
every step required for effective immunity, from deregulation of antigen-presenting cells, to
establishment of a physical barrier at the vasculature that prevents homing of effector tumor-
rejecting cells, and through the suppression of effector lymphocytes through the recruitment and
activation of immunosuppressive cells like myeloid-derived suppressor cells (MDSCs),
tolerogenic monocytes and T regulatory cells (Tregs). Here, we review the ways in which tumors
exert immune suppression and highlight the new therapies that seek to reverse this phenomenon
and promote anti-tumor immunity. Understanding anti-tumor immunity, and how it becomes
disabled by tumors, will ultimately lead to improved immune therapies and prolonged survival of
patients.
Introduction
The immune response against tumors is mounted by a multitude of immune cells. However,
T cells remain potent mediators of anti-tumor immunity, and tumor infiltration by T cells is
a good prognostic marker in a number of tumor types including ovarian, colon, breast renal,
prostate, and cervical cancers (Galon et al., 2006; Hwang et al., 2012; Ma et al., 2012; Naito
et al., 1998; Piersma et al., 2007; Zhang et al., 2003). The steps leading to an antitumor
immune response are depicted in Figure 1. In some patients, these responses are activated
spontaneously, but chemotherapy is also thought to promote antitumor immune responses.
Typically, the immune response begins at the tumor site, where professional antigen
presenting cells (APCs) take up tumor antigens to be processed. These antigens may be
some of the many mutational neo-antigens (Robbins et al., 2013), non-mutated genes that
are overexpressed by cancer cells, or differentiation antigens related to the cancer’s tissue of
origin (Segal et al., 2008). Although T cell priming is traditionally thought to occur
exclusively in tumor-draining lymph nodes, spontaneously organized tertiary lymphoid
organ features can be also encountered in tumors (de Chaisemartin et al., 2011), suggesting
that T cell education can occur within the tumor stroma. Dendritic cells from tumors may
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present antigens in a tolerizing manner, stimulating T regulatory (Treg) cells (Steinman et
al., 2000), which would oppose an antitumor response. In order to promote immunity rather
than tolerance, it is believed that APCs require a robust maturation signal. Toll-like receptor
(TLR) signaling from necrotic tumors cells may induce partial maturation (Cavassani et al.,
2008), but chemotherapy drugs that induce immunogenic cell death can also stimulate an
immune response (Zitvogel and Kroemer, 2009). Activated dendritic cells can also drive B
and NK cell (Mellman and Steinman, 2001) responses that can play important roles in
antitumor immunity. The exact type of T cell response required for optimal anti-tumor
immunity is not entirely clear, however a potent CD8+ effector T cell response is certainly
necessary. Additionally, either a CD4+ T helper 1 (Th1) or Th17 directed response appear to
promote CD8+ effector T cell responses (Martin-Orozco et al., 2009; Mellman and
Steinman, 2001; Steinman et al., 2000). Given that TILs are such an important prognostic
marker for tumor progression across multiple tumor types, understanding the processes
involved in their suppression is essential to developing new therapeutic strategies. In this
review, we will detail the ways in which tumors suppress each step in the generation of an
effective anti-tumor immune response, from generation of tumor-specific T cells, to their
homing, engraftment and effective recognition of tumors. We also discuss recent and
potential future therapeutic interventions to circumvent tumor-mediated
immunosuppression.
Generation of tumor-reactive T cells
Dendritic cells (DCs) are extremely important for the coordination of an anti-tumor immune
response. As professional APCs, they present tumor antigens to both B cells and T cells,
generating an antigen-specific antitumor response. Tumors have a profound effect on the
functions of dendritic cells (Gabrilovich, 2004). Defective dendritic cell function is often
combined with deregulation of DC maturation, and in humans as well as in the mouse,
tumor-infiltrating cells expressing DC markers also express markers of macrophages and
immature monocytes, indicating recruitment of myeloid precursors with incomplete
differentiation (Conejo-Garcia et al., 2004). Dendritic cells can have significant
heterogeneity both in vitro and in vivo (Hashimoto et al., 2011), and include resident and
bone-marrow derived myeloid dendritic cells and plasmacytoid dendritic cells. These cells
have different functional properties, and they may contribute differently to tumor tolerance
or rejection (Kim et al., 2007). For example, although DCs are important APCs, depletion of
CD11c+ cells (primarily DCs) can actually inhibit tumor growth (Huarte et al., 2008), an
effect that reflects the role of tumor-coopted tolerogenic dendritic cells in establishing tumor
tolerance and dissemination (Labidi-Galy et al., 2011; Sawant et al., 2012).
Most tumor myeloid DCs present a phenotype of partially mature DCs expressing
intermediate amounts of MHC class I and II and costimulatory molecules, and high amounts
of coinhibitory molecules and immunosuppressive cytokines. In the mouse, such cells are
unable to elicit antigen-specific effector T cells (Conejo-Garcia et al., 2004). Human DCs
isolated from breast, neck/head, and lung cancer patients were also functionally impaired in
a mixed leukocyte reaction, and this functional impairment corresponded to a more severe
cancer diagnosis (higher stage) (Almand et al., 2000). Immature, or incompletely matured
DCs may mediate tumor tolerance, inducing anergy of effector T cells and/or expansion of
Treg cells in the lymph nodes or at tumor sites (Lutz and Schuler, 2002; Mahnke et al.,
2002).
Gabrilovich and colleagues were the first to identify VEGF as a tumor factor capable of
impairing both dendritic cell function and maturation from CD34+ hematopoietic precursors
(Gabrilovich et al., 1996). Similar observations of defective DCs in cancer patients, with a
dependence on or association with VEGF, have since been made (Della Porta et al., 2005;
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Takahashi et al., 2004). VEGF is an important regulator of hematopoiesis, and its artificial
overexpression has led to widespread changes in the differentiation of multiple
hematopoietic lineages. In patients, treatment with the VEGF blocking antibody
bevacizumab has been shown to reverse maturation defects of in DCs (Almand et al., 2000;
Fricke et al., 2007; Osada et al., 2008). Defective DC maturation that is reversible with
VEGF blockade was also found in mouse models (Gabrilovich et al., 1999; Nair et al., 2003;
Roland et al., 2009; Ishida et al., 1998). VEGF likely exerts effects on dendritic cells beyond
its role in the suppression of normal hematopoiesis. Programmed death ligand 1 (PD-L1) is a
major negative regulatory ligand of the B7 family that engages the cognate programmed
death-1 (PD-1) receptor expressed on activated T cells, which transduces a signal that
inhibits T-cell proliferation, cytokine production, and cytolytic function (Riley, 2009). PD-
L1 is expressed on tumor cells, but it is also highly expressed on tumor-associated myeloid
DCs in ovarian cancer patients (Curiel et al., 2003). Incubation of blood myeloid DCs with
VEGF induced robust expression of PD-L1 on the cell surface offering a potential
mechanism by which VEGF affects DC function (Curiel et al., 2003).
A number of other tumor-derived soluble mediators can also disrupt DC function and play
critical role in defining the semi-mature, tolerogenic phenotype of tumor DCs, including
transforming growth factor β (TGFβ) (Geissmann et al., 1999), interleukin 10 (IL-10)
(Steinbrink et al., 1999), as well as macrophage colony-stimulating factor (M-CSF) and IL-6
(Menetrier-Caux et al., 1998). IL-10 also induces PD-L1 expression on DCs (Curiel et al.,
2003). Additional mechanisms can contribute to DCs with a tolerogenic phenotype.
Physiological stimuli found in the tumor microenvironment such as hypoxia (Elia et al.,
2008) and lactic acid (Gottfried et al., 2006) can also influence DC phenotype and function.
In vitro, DCs differentiated under these exposures tend to have a less mature phenotype,
express immunosuppressive molecules like indoleamine 2,3-dioxygenase (IDO) and
prostaglandin E2 (PGE2), and fail to stimulate T cells efficiently (Elia et al., 2008;
Gabrilovich et al., 2012; Gottfried et al., 2006). In particular, PGE2 signaling on DCs can
induce the expression of immunosuppressive molecules such as IL-10 (Kalinski et al., 1997)
and IDO (Braun et al., 2005), can suppress IL-12 production (Watchmaker et al., 2010), and
inhibit chemokine expression (Muthuswamy et al., 2010).
Thus, it is not surprising that in many patients there are no detectable tumor-reactive T cells.
For example, in ovarian cancer, tumor-reactive T cells were detected in the peripheral blood
of only half the patients tested (Schlienger et al., 2003). The defective phenotype of DCs
may contribute in more ways to deregulate T cell tumor attack, as properly mature DCs that
express costimulatory ligands may be required in the periphery at the inflammatory site, to
maintain an effective effector CD8+ T cell response (Dolfi et al., 2011), and these are
typically absent in the tumor microenvironment. Finally, defective DCs fail to secrete
appropriate chemokines that play a critical role in recruiting effector cells to tumors
(Muthuswamy et al., 2012). As described above, disruption of normal DC function is an
essential component of tumor-mediated immune suppression leading to tumor immune
tolerance, and strategies aimed at relieving this immune suppression, or generating potent
DC-vaccines ex vivo, is an active area of research that has already enjoyed some early
successes.
Reaching the tumor site
Tumors have developed a number of unique ways to suppress the recruitment of T cells to
the tumor site. The exact mechanisms have not been fully elucidated, but the disruption of
normal chemokine elaboration is believed to be a contributing factor. Chemokines play a
critical role in orchestrating T cell trafficking and the specialization of immune responses,
and their alteration is probably tissue-specific. Of particular interest is the observation that
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tumors with high numbers of T cells express high amounts of established T cell-attracting
chemokines including chemokine (C-C motif) ligand 2 (CCL2), CCL3, CCL4, CCL5,
chemokine (C-X-C motif) ligand 9 (CXCL9), and CXCL10 (Harlin et al., 2009). It is
unclear whether this is the result of an initial T cell activation, unleashing a chemokine
response furthering T cell recruitment. However, the pattern of T cell infiltration in mouse
models suggests that a few T cells infiltrate tumors initially, followed by a large influx of
both specific and nonspecific T cells (Boissonnas et al., 2007). In skin tumors, aberrant
epidermal growth factor receptor (EGFR)-Ras signaling has been shown to suppress the
production of CCL27, a chemokine constitutively expressed by normal keratinocytes, and
disruption of CCL27 expression in vivo prevented T cell homing to skin tumors and
accelerated tumor outgrowth in a mouse model (Pivarcsi et al., 2007).
Tumor cells are well-known for aberrant post-translational modifications, and changes in
cleavage, glycosylation, or deamination could result in dramatically altered activities of
expressed chemokines (Loos et al., 2009); (Proost et al., 2007). For example, CCL2, an
important chemokine for the recruitment of cytotoxic lymphocytes (CTLs) to the tumor site
(Brown et al., 2007), undergoes nitrosylation induced by reactive nitrogen species, which
abrogates its ability to attract tumor-specific CTLs, although it can still attract myeloid cells
(MDSCs) to the tumor (Molon et al., 2011), highlighting a potent mechanisms of immune
suppression. Furthermore, altered proteolytic processing of CXCL11, an important
chemokine recruiting CXCR3+ effector T cells, can impair binding and signaling of the
chemokine, ultimately reducing lymphocyte migration (Boissonnas et al., 2007; Harlin et al.,
2009; Proost et al., 2007). Thus, deregulation of chemokine circuitries appears to be an
important mechanism preventing proper orchestration of immune tumor rejection
mechanisms.
Crossing the tumor vasculature
Although T cells can accumulate in the tumor stroma, they often fail to penetrate deeply into
tumors in the epithelial compartment (Zhang et al., 2003; Boon et al., 2006; Dudley et al.,
2002; Lurquin et al., 2005). The vascular endothelium plays a key role in leukocyte
trafficking and mounting evidence indicates that the tumor vasculature establishes an active
barrier that tumor-reactive T cells must cross in order to recognize and eliminate their tumor
targets (Figure 2) (Boon et al., 2006; Dudley et al., 2002; Lurquin et al., 2005). Successful
transmigration through the tumor endothelial barrier is required for optimal tumor
regression. The prohibitive nature of the tumor endothelium can be mediated by the type and
quantity of adhesion molecules expressed (Zitvogel et al., 2006) and is presumably
maintained by local soluble tumor factors (Zitvogel et al., 2006), but precisely how the
tumor vasculature establishes immune privilege is not well known.
T cells extravasate through the endothelium to the tumor in multi-step process that includes
rolling and adhesion to endothelial cells, followed by diapedesis. Although the precise
mechanisms are not entirely known, the consensus view is that in the tumor
microenvironment angiogenic molecules, including VEGF, inhibit adhesion molecule
expression on endothelial cells (Bouzin et al., 2007; Detmar et al., 1998; Dirkx et al., 2003;
Griffioen et al., 1996a; Griffioen et al., 1996b; Min et al., 2005). Tumor necrosis factor-
alpha (TNFα) is often expressed within the tumor microenvironment and is expressed, albeit
in low amounts, by many malignant cells (Balkwill, 2009). Although TNFα is an activator
of endothelial cells and T cell adhesion, in the presence of angiogenic growth factors like
basic fibroblast growth factor (bFGF) or VEGF (Bouzin et al., 2007; Griffioen et al., 1996b)
TNFα-induced T cell adhesion is minimal. In the presence of VEGF, TNFα stimulation is
unable to induce expression of molecules intercellular adhesion molecule-1 (ICAM-1) and
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vascular cell adhesion molecule (VCAM-1) on endothelial cells (Bouzin et al., 2007;
Griffioen et al., 1996b).
Endothelins and their receptors are upregulated in a number of cancers including ovarian,
breast, renal, colon, and prostate cancer (Bagnato and Rosano, 2008; Nelson et al., 2003).
Endothelin (ET) peptide ligands, ET-1, 2, 3, and 4 (Saida et al., 1989; Yanagisawa and
Masaki, 1989) are potent regulators of endothelial cell biology and are involved in
autocrine/paracrine loops that promote proliferation, protection from apoptosis,
angiogenesis, vasculogenesis, and invasion and metastatic dissemination of tumors (Bagnato
and Rosano, 2008; Nelson et al., 2003). Endothelins signal through two G protein-coupled
receptors (GPCR), the endothelin-A receptor (ETAR) and ETBR, which exert opposite
effects on the vasculature (Frommer and Muller-Ladner, 2008; Meidan and Levy, 2007).
The use of specific endothelin receptor antagonists has been demonstrated to slow tumor
growth in patients, or prevent tumor growth in mouse models (Bagnato and Rosano, 2008;
Nelson et al., 2003). Endothelins interact with VEGF to regulate multiple aspects of
angiogenesis including endothelial cell proliferation, migration, invasion, vessel formation,
and neovascularization (Nelson et al., 2003). ET-1 can directly promote the expression of
VEGF in cancer cell lines in vitro (Rosano et al., 2003; Salani et al., 2000; Spinella et al.,
2007; Spinella et al., 2002), likely through increased HIF-1α expression (Salani et al., 2000).
Furthermore, there is a correlation between ETBR and VEGF expression in a number of
different tumor specimens (Kato et al., 2001). In addition to regulating vascular tension and
angiogenesis, ETBR was recently demonstrated to suppress endothelial adhesion and T cell
infiltration in tumors (Buckanovich et al., 2008). Endothelial ETBR was upregulated in
ovarian tumors lacking intraepithelial tumor-infiltrating lymphocytes (TILs) (Buckanovich
et al., 2008) and, similar to the absence of intraepithelial TILs (Zhang et al., 2003), ETBR
overexpression was associated with poor survival. Endothelin 1 (ET1) signaling through
ETBR was found to block T cell adhesion to the endothelium through suppression of
ICAM-1 clustering on endothelial cell membranes (Buckanovich et al., 2008). ET1 is
overexpressed in ovarian cancer (Bagnato et al., 1999), establishing a tumor cell–
endothelium ET1–ETBR paracrine axis, which is upregulated specifically in the tumor
microenvironment and suppresses T cell adhesion to endothelium, even in the presence of
increased TNFα.
The imunosuppressive effects of VEGF as well as ETBR on tumor endothelium appear to be
commonly mediated by nitric oxide (NO), as specific NO antagonists can abrogate the
deregulation of CAMs induced by either molecule and restores T cell adhesion
(Buckanovich et al., 2008; Bouzin et al., 2007). NO is a gaseous molecule and a highly
reactive free radical. NO is highly important in the control of vascular functions regulating
angiogenesis, vascular permeability, blood flow, and leukocyte-endothelial interactions
(Fukumura et al., 2006). In tumors, inhibition of the NO producing enzyme, nitric oxide
synthase (NOS), enhanced both rolling and adhesion of leukocytes on tumor vasculature
(Fukumura et al., 1997). Although this effect may be due in part to direct effects of NO on T
cells (Lukacs-Kornek et al., 2011; Bronte et al., 2005), NO also has a direct effect on
endothelial cells that may limit anti-tumor immunity. NO reduces leukocyte-endothelial
interactions by reducing the expression of important adhesion molecules P-selectin,
ICAM-1, and VCAM-1, and conversely, NOS inhibitors increase expression of these
adhesion molecules and leukocyte binding in normal blood vessels (De Caterina et al., 1995;
Davenpeck et al., 1994; Kubes et al., 1991). Further, mice genetically deficient in the
enzymes responsible for NO synthesis displayed enhanced leukocyte-endothelial
interactions driven by P-selectin (Lefer et al., 1999).
It is emerging that the tumor vasculature also can shape the nature of T cell infiltration in
tumors thorough mechanisms independent of adhesive interactions. Endothelial cells can for
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example express a number of mediators that suppress or kill effector lymphocytes such as
Fas ligand (FasL) (Sata and Walsh, 1998), TNF-related apoptosis-inducing ligand (TRAIL)
(Secchiero and Zauli, 2008), and possibly even CD31, a classical endothelial cell marker
(Ma et al., 2010). Tumor endothelial cells can also express a robust repertoire of
immunosuppressive molecules, both soluble and surface expressed including PD-L1 and
PD-L2 (Frebel et al., 2012; Mazanet and Hughes, 2002; Rodig et al., 2003), B7-H3 (Zang et
al., 2010), TIM-3 (Huang et al., 2010), and IL-10, TGFβ, and PGE2 (Hernandez et al., 2001;
Pirtskhalaishvili and Nelson, 2000). Metabolic disruption of T cells through IDO expression
(Batista et al., 2009; Blaschitz et al., 2011; Riesenberg et al., 2007) and arginase I (Fu et al.,
2011) by endothelial cells has also been suggested, but whether these mechanisms are active
in tumors are unknown. Thus, the function of tumor endothelial cells is largely
immunosuppressive, maintained by tumor cells through paracrine mechanisms (Mulligan et
al., 2009; Mulligan and Young, 2009).
Negotiating the tumor stroma space and suppressive leukocytes
The effector T cells that manage to cross the endothelial barrier must navigate the tumor
stroma until they encounter tumor cell targets. Many opportunities for encountering
immunosuppressive signals exist within this space. Although resident stromal and immune
cells can certainly contribute to immune suppression within the tumor microenvironment
(Aggarwal and Pittenger, 2005; Dranoff and Fearon, 2013; Engels et al., 2012;
Kammertoens et al., 2005; Motz and Coukos, 2011), immunosuppressive leukocyte
populations such as Treg cells (Facciabene et al., 2012) and myeloid-derived suppressor
cells (MDSCs) (Gabrilovich and Nagaraj, 2009) are also actively recruited and undergo
local expansion to effectively suppress T cell effector functions. Infiltration of these cells
types is frequently associated with a poor prognosis.
CD4+CD25+FoxP3+ Treg cells can be divided into natural Tregs (nTreg), which are derived
from the thymus and maintained peripherally by TGFβ, and inducible Tregs (iTreg), which
are induced from naïve CD4+ T cell precursors and exert suppressive functions similar to
those observed for nTregs, controlled in both Treg subtypes by the forkhead box P3 (FoxP3)
transcription factor (Curotto de Lafaille and Lafaille, 2009). Several studies have determined
that Tregs that accumulate within tumors are generally clonally restricted (Sainz-Perez et al.,
2012), and are specific for tumor antigens (Bonertz et al., 2009), expressing different T cell
receptor (TCR) sequences than local effector T cells (Sainz-Perez et al., 2012). Treg are thus
activated in an antigen-specific manner, but can suppress T cell function non-specifically
through several mechanisms (Facciabene et al., 2012; Vignali et al., 2008). Tregs secrete
soluble mediators such as TGFβ, IL-10, and IL-35, which can suppress effector T cell
expansion and cytokine secretion (IFNγ, TNFα). Specifically, TGFβ and IL-10 have been
shown experimentally to make significant contributions to tumor progression by attenuating
antitumor immunity (Loser et al., 2007; Strauss et al., 2007). Although IL-2 signaling on
Tregs is not required for their suppressive function, Tregs require IL-2 support to maintain
metabolic homeostasis and their competitive fitness in vivo, (Fontenot et al., 2005). Thus,
Treg cells depend on paracrine support from T effector cells, which secrete IL-2, for
expanding and maintaining local tolerance. It is also believed that because of higher
expression of the IL-2 receptor alpha (IL-2Rα, also known as CD25), Tregs can act as an
IL-2 sink, “starving” effector T cells of IL-2 particularly within the tumor
microenvironment, thus limiting effector T cell expansion and function (Pandiyan et al.,
2007). In addition, Treg cells can suppress CTLs through the generation of adenosine
(Deaglio et al., 2007). Tregs can also directly kill T cells via cytolysis mediated by TRAIL
(Ren et al., 2007) or granzyme B (Gondek et al., 2005). Finally, Tregs can engage in
crosstalk with DCs, inducing the expression of IDO, IL-10, and TGFβ expression from DCs
through direct interactions (Facciabene et al., 2012).
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Treg cells are actively recruited by tumors, and their accumulation has been associated with
poor prognosis in some studies (Curiel et al., 2004). Chemokine ligand CCL22 is a potent
Treg chemoattractant expressed in high amounts by both tumor cells and tumor
macrophages recruiting Treg through C-C chemokine receptor 4 (CCR4) in ovarian cancer
(Curiel et al., 2004) and Hodgkin’s lymphoma (Ishida et al., 2006). Recently, a link between
Treg recruitment and hypoxia was discovered in ovarian cancer. Hypoxic ovarian cancer
cells were shown to upregulate preferentially CCL28 among all chemokines (through
hypoxia-inducible factor), which recruited CD4+CD25+FoxP3+ Treg cells through the
cognate receptor CCR10 expressed preferentially on Tregs among T cell subsets
(Facciabene et al., 2011). Forced overexpression of CCL28 in mouse ovarian cancer cells
led to enhanced growth of intraperitoneal tumors, characterized by increased Treg
infiltration and accelerated tumor growth (Facciabene et al., 2011). Of importance, depletion
of CD25+ or CCR10+ cells eliminated Tregs from CCL28-overexpressing tumors and
abrogated the tumor growth advantage conferred by CCL28 overexpression. It was found
that besides immune suppression, CCL28-recruited Treg cells reprogrammed the tumor
microenvironment towards angiogenesis (Facciabene et al., 2011). Recruitment of Tregs to
areas of hypoxia could enhance their immunosuppressive capacity, as hypoxia-exposed
Tregs are more effective at suppressing the proliferation of effector T cells (Ben-Shoshan et
al., 2008).
In addition to recruiting nTregs, the tumor microenvironment promotes the continued
expansion of nTregs (Valzasina et al., 2006) as well as the generation of iTregs (Liu et al.,
2007). It is believed that IL-10 (Seo et al., 2001), TGFβ (Chen et al., 2003), and adenosine
(Zarek et al., 2008) derived from either tumor cells or tumor-resident immunosuppressive
DCs (Ghiringhelli et al., 2005) and Tie-2+ monocytes (TEMs) (Coffelt et al., 2011; Liu et
al., 2007) may be responsible for this. Furthermore, TEMs can expand Tregs in vitro in a
CD86-dependent manner, and in breast cancer patients TEMs expressing high amounts of
CD86 are associated with high numbers of Tregs (Ibberson et al., 2013). CD86 expression in
TEMs is dependent on TIE-2 and VEGFR signaling in vitro (Ibberson et al., 2013),
highlighting the contribution of angiogenesis to this phenomenon.
There are a number of myeloid lineage cells that accumulate within tumors, but perhaps the
best studied are MDSC. These cells are often found in large numbers within tumor sites as
well as in the peripheral blood of cancer patients, and are potent inhibitors of effector T cell
functions (Gallina et al., 2006). These cells can contribute to the suppression of T cells
through production of arginase I and reactive oxygen species (ROS), IL-10 and TGFβ
[reviewed by (Gabrilovich and Nagaraj, 2009)]. Additionally, MDSCs may expand Tregs
within the tumor site (Huang et al., 2006). MDSCs may be recruited from the bone marrow
and expanded in the peripheral blood through interactions with BV8 and endocrine-gland-
derived VEGF (EG-VEGF) (LeCouter et al., 2004; Lin et al., 2002; Shojaei et al., 2007).
Once in the blood, MDSCs can be recruited to tumors by a number of chemokines such as
CCL2, CXCL5, CXCL12 and stem cell factor (SCF) (Murdoch et al., 2008). Expression of
both BV8 and CXCL12 are increased by hypoxia (Du et al., 2008), so in a similar manner to
Tregs, MDSCs may be recruited to sites of tumor hypoxia where they may directly influence
angiogenesis. Once in the tumor, MDSCs exert potent effects on T cell effector function, but
they also control other key events in tumors. Injection of MDSCs into tumors significantly
enhanced blood vessel development (Yang et al., 2004), and tumor angiogenesis was
reduced in tumor-bearing mice treated with a neutralizing anti-BV8 antibody, that reduced
the numbers of infiltrating MDSC (Shojaei et al., 2007). However, MDSCs have been
shown to have phenotypic plasticity, and they can acquire the characteristic of tumor-
rejecting monocytes and even APCs given the right conditions are met. For example,
cytokines like IL-12 and IFNγ have been shown to convert MDSCs into an APC-like cell
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that activates and enhances the functions of T cells either in vitro (Bronte et al., 2000) or in
vivo (Kerkar et al., 2011).
The encounter with tumor cells
After T cells finally make their way through the barriers of the tumor vasculature and
stroma, they are faced with a number of immunosuppressive factors that prevent effective
recognition and/or attack of tumor cells (Figure 3). This topic has been reviewed extensively
elsewhere (Whiteside, 2006; Zou, 2005). T cells depend largely on recognition of targets
through major histocompatibility complex (MHC)-TCR interactions. It has become quite
obvious that tumors express unique protein products that can be recognized by the immune
system as ‘non-self’, ranging from overexpressed self proteins including cancer testis and
other immune privileged site antigens, to novel mutational epitopes resulting from non-
synonymous somatic mutations. Although most tested tumors harbor tens to hundreds of
such mutations (Vogelstein et al., 2013), many of these epitopes are candidates for
presentation (Segal et al., 2008), and T cells recognizing such tumor rejection epitopes have
been recently identified in melanoma (Robbins et al., 2013), it is not known whether these
mutations are in fact transcribed, translated in mutated protein products, or finally included
in peptides presented on surface MHC molecules in all tumors. Many tumors presumably
manage to eliminate presentation of immunogenic peptides through loss of expression or
downregulation of the antigen presenting machinery, occurring in both MHC Ia (classical)
(Marincola et al., 2000) and MHC Ib (non-classical) presentation (Carosella et al., 2003);
(Rodgers and Cook, 2005). There are a multitude of mechanisms responsible for this
aberrant expression, possibly stemming from selective pressure ranging from mutation,
genetic loss, and epigenetic silencing of expression (Chang et al., 2005). This reduction is
associated with histopathological markers of poor prognosis of disease and poor clinical
outcomes (Marincola et al., 2000). However, the demonstration that CD8+ T cells
recognizing mutational epitopes are already present in tumors and can in fact reject them
under the optimized conditions of adoptive transfer, indicates that at the steady state tumors
manage to attenuate recognition and attack by these T cells (Carosella et al., 2003; Chang et
al., 2005; Marincola et al., 2000). Tumors express surface molecules that can directly kill T
cells particularly of the TNF family of genes that include FasL and TRAIL (Whiteside,
2002). They can also express surface proteins such as PD-L1 and PD-L2 (Hamanishi et al.,
2007) and B7-H4 (Kryczek et al., 2006), which can suppress T cell functions and arrest
tumor rejection (Hirano et al., 2005; Munn and Mellor, 2004; Whiteside, 2002). In addition,
the microenvironment close to tumor cells may be quite toxic for optimal CTL function.
Tumors secrete a number of soluble mediators that can directly inhibit CTLs such as TGFβ,
IL-10, PGE2, histamine, hydrogen peroxide, and adenosine (Whiteside, 2002). Deprivation
of metabolic substrates due to competitive consumption by tumor cells and/or active
depletion by enzymes such as IDO and arginase (Munn and Mellor, 2004) can further
attenuate T cell effector function. Finally, the hypoxic conditions (Palazon et al., 2012) and
the relatively lower extracellular pH characterizing the tumor interstitium can negatively
affect CTL function (Aggarwal and Pittenger, 2005; Mendler et al., 2012)
Therapies to restore antitumor immunity
The generation of competent tumor-specific CTLs and their recognition and rejection of
tumor cells seems like an impossible task. Yet, recent successes indicate that this can be
achieved in a proportion of patients with existing therapeutic means. It is obvious that most -
if not all - tumors are potentially immunogenic, but the endogenous immune response is
either entirely paralyzed or ineffective. Thus, major efforts should focus on attenuating
tumor-associated immune suppression. Presently, there are multiple opportunities to target
immunosuppressive pathways and mobilize antitumor immunity in vivo or ex vivo.
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Effective antitumor T cells can be expanded ex vivo from natural TILs, from endogenous
high-avidity T cell clones recognizing tumor-associated antigens, or from T cells transduced
with exogenous cloned TCRs or chimeric antigen receptors (CARs), while the host can be
conditioned by lymhodepletion to optimize their engraftment; endogenous T cells can also
be effectively activated by pharmacologic checkpoint inhibitors; the vasculature can be
disrupted by low-dose metronomic chemotherapy or normalized by drugs targeting
angiogenesis; soluble immunosuppressive factors such as IDO, IL-6, IL-10, TGFβ, and
PGE2 can be individually blocked by specific pharmacologic inhibitors; suppressor cells can
be depleted by specific chemotherapy drugs such cyclophosphamide (e.g. for Treg cells) or
gemcitabine (e.g. for MDSCs); endogenous tumor-specific T cell immunity can be
effectively boosted by exogenous vaccines; and tumor-associated antigen-presenting cells
can be activated by specific drugs, including Toll-like receptor agonists, while tumor
antigens can be released in situ by immunogenic cell death induced by specific
chemotherapy drugs or radiation. The complexity of the immunosuppressive mechanisms at
the tumor microenvironment and the availability of multiple therapeutic opportunities render
the clinical advancement of cancer immunotherapy strategies a daunting task. The rational
design of therapeutic strategies could be aided by classifying tumors based on the presence
of pre-existing immunity. Robust biomarkers of pre-existing tumor immunity have not been
validated yet, but TILs demonstrated by immunostaining could be a reasonable biomarker to
classify tumors in those that already have pre-existing TILs, and those that do not. There is
to date no data available on whether the TIL biomarker can predict responses to checkpoint
blockade or other therapies activating T cells (such as bispecific antibodies) due to the lack
of pre-treatment biopsies in most clinical trials. However, this classification could help
designing immunomodulatory therapy, as immune escape mechanisms are likely to be quite
different between these two main tumor immunophenotypes, at least with respect to T cell
homing and engraftment. Validation of TILs is urgently needed to assess whether their
presence in human tumors is a robust indication of endogenous antitumor immune response.
Below, we discuss a number of immune therapies that have shown clinical efficacy or are
under clinical development.
Tumors with pre-existing TILs
In tumors with pre-existing TILs, one can assume that the tumor microenvironment does not
offer major barriers to T cell homing. Furthermore, the detection of tumor-reactive TILs
would provide a strong indication that the tumor microenvironment does not entirely
paralyze antigen-presenting mechanisms or the engraftment of tumor-reactive T cells. In
melanoma, the success of adoptive TIL therapy is a testament to this hypothesis; all patients
who receive TILs are preselected based on the availability of expandable tumor-reactive
TILs, and a significant proportion of them experience objective responses. Thus, these TILs
can reject tumors when appropriately activated and expanded, indicating that proper T cell
activation is a major issue in these tumors, and that mechanisms limiting the function of
CTLs must be operating in these tumors at the steady state. Attenuation of these
immunosuppressive mechanisms could lead to clinical responses in many of these tumors.
The first convincing evidence that activation of CTLs could produce objective clinical
benefit in a significant number of patients was provided by Ipilimumab, a monoclonal
antibody directed against CTLA-4 (cytotoxic T lymphocyte activation marker 4). CTLA-4 is
a potent negative regulator of T cell activation that binds to members of the B7 family of co-
stimulatory molecules (Chambers et al., 2001). Binding of CTLA-4 inhibits activation of T
cells, thus attenuating excessive T cell activation. The significance of CTLA-4 as a negative
regulator of the immune response comes from CTLA-4 knockout mice, which die at a very
early age of autoimmune toxicity (Waterhouse et al., 1995). Ipiliumab has shown an overall
survival benefit in two randomized, phase III trials in patients with advanced melanoma
(Hodi et al., 2010; Robert et al., 2011). Although the response rates were modest, between
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10% and 15%, a significant survival advantage was observed in the treated populations. The
mechanisms of action of CTLA-4 blockade are still debated, including disinhibition of
CTLA-4+ tumor-reactive TILs, but also depletion of CTLA-4high activated Treg cells (Egen
et al., 2002; Kwon et al., 1999; Selby et al., 2013; Sutmuller et al., 2001; van Elsas et al.,
2001).
PD-1 is an additional coinhibitory receptor expressed on activated T cells. Its function is
important in peripheral tissues, where T cells can encounter the PD-1 ligands PD-L1 (B7-
H1) and PD-L2 (B7-DC), which are expressed by tumor cells, stromal cells, or both (Dong
et al., 2002). Inhibition of PD-1 signaling can enhance T-cell responses both in vitro and in
vivo in preclinical tumor models (Iwai et al., 2002). In complementary pilot clinical studies
using either anti-PD1 or anti-PD-L1 antibody, a large number of patients have demonstrated
objective clinical responses (Brahmer et al., 2012; Topalian et al., 2012). Patients who
responded the greatest appeared to be those whose tumors expressed PD-L1. Besides
melanoma and renal cell cancer, patients with lung cancer and other solid tumors have
shown objective responses, validating that tumor immunogenicity is a universal tumor
property and it is not restricted to few tumor types traditionally considered immunogenic. A
variety of additional coinhibitory (LAG-3, TIM-3, BTLA, 2B4, KLRG-1, CD160, etc) and
costimulatory receptors (CD28, 4-1BB, OX-40, GITR etc.) have been identified. Their
significance as therapeutic targets, whether complementary or redundant, will require
careful preclinical characterization and clinical testing. Despite encouraging preclinical
results with dual blockade of PD-1 and CTLA-4 (Duraiswamy et al., 2013), clinical data is
still being accumulated (trial number NCT01024231). However, the fact that many patients
still do not respond to CTLA-4 and/or PD-1 blockade may suggest that additional signals are
required to effectively rescue TIL function.
An additional approach to activating TILs is the use of bispecific antibodies. This approach
relies on the use of recombinant antibody structures with dual specificity that simultaneously
engage both the TIL and an antigen on the tumor cell surface (Kontermann, 2012). For
example, a recent approach using a bispecific antibody that recognizes both CD3ε (T cell
activating domain) and CD19 (tumor-binding domain) achieved impressive clinical success
(Topp et al., 2011). This approach could be used in a number of additional tumor targets to
promote activation of TILs within the tumor microenvironment. This method activates TILs
in a non-specific manner and therefore does not rely on the presence of endogenous tumor-
specific T cells. However, tumors with pre-existing TILs may be more prone to respond,
given that TILs are already available at the tumor microenvironment, and homing of
additional T cells is not prevented by obvious local barriers.
Tumors lacking pre-existing TILs
Whereas tumors with pre-existing TILs appear intrinsically more immunogenic and easier to
approach therapeutically, tumors lacking TILs may be more complex. Experiments in the
mouse indicate that effective checkpoint blockade may not be sufficient to reenact tumor
rejection mechanisms, and additional therapeutic interventions may be required to mobilize
antitumor immunity (Kwon et al., 1999; Sutmuller et al., 2001; van Elsas et al., 2001). The
molecular basis of immune escape in these tumors may be downregulation of the antigen
presenting machinery in tumor cells, which may be due to epigenetic deregulation, and can
be reversed with histone deacetylase inhibitors (Magner et al., 2000) or the use of low-dose
IFNγ (Propper et al., 2003). Alternatively, a prohibitive tumor endothelial barrier may be the
reason why T cells may not be able to home to tumors (Kandalaft et al., 2011).
Proangiogenic signals can deregulate adhesive properties of the tumor endothelium and thus
antiangiogenesis therapy could be contributory to activate antitumor immune response
(Motz and Coukos, 2011). VEGF blockade in a transgenic mouse model of Her2/neu-driven
breast cancer induced a de novo TIL infiltrate, which was responsible for enabling the
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therapeutic efficacy of VEGF blockade, as CD8+ T cell depletion abrogated the therapeutic
efficacy of the anti-VEGFR-2 antibody DC101 (Manning et al., 2007). Given that VEGF
inhibition has not proven beneficial in many human solid tumor types (Ebos and Kerbel,
2011), alternate or combinatorial approaches to block angiogenesis may be required. Lastly,
given the likely paucity of pre-existing T cells in these tumors, maneuvers that expand the
pool of tumor-specific T cells could prove beneficial. Molecularly defined monovalent
vaccines have failed to produce substantial responses to date, but whole tumor antigen
vaccines have performed better (Neller et al., 2008) and can greatly enhance checkpoint
blockade to produce effective rejection of non-immunogenic tumors (Duraiswamy et al.,
2013). This is possibly because they comprise all the potential mutational epitopes in
addition to any other immunodominant epitopes. Future vaccine development based on
mutational epitopes will test this hypothesis (Castle et al., 2012). Alternatively, in situ
vaccination with exposure of tumor antigen through the use of immunogenic chemotherapy
or radiation, in combination with tumor APC activation using appropriate Toll-like receptor
agonists, could lead to the generation of tumor-reactive T cells and a switch of the tumor
chemokine microenvironment by activated innate immune cells.
Specific targeting of immunosuppressive cells
In addition to promoting the activity of anti-tumor T cells, a number of approaches are
aimed at inhibiting immune suppression within the tumor microenvironment. Specifically, a
number of therapies have been developed to specifically deplete major immunosuppressive
cells types. Reviewed extensively by Facciabene and colleagues (Facciabene et al., 2012), a
number of direct and indirect methods exist to deplete Tregs within the tumor
microenvironment. These include specific depletion with monoclonal antibodies (anti-
CD25) and depletion with the use of chemotherapeutics such as cyclophosphamide
(Facciabene et al., 2012). Further, additional immune cell targets like MDSCs have shown
pre-clinical successes (Shojaei et al., 2007). This remains an area of active research.
Facing and deconvoluting the molecular complexity of tumor immune
suppression
After decades of disappointment in immunotherapy, cancer immunotherapy using adoptive
transfer of T cells or therapeutic antibodies that neutralize key checkpoint mechanisms (e.g.
CTLA-4 or PD-1) has finally met the long-standing expectation to result in significant and
reproducible clinical benefits. Immunotherapy is thus a feasible path forward to obtaining
durable, long-lasting responses in cancer patients. Yet, many patients fail to respond, and
among those who respond, many do not draw long-lasting benefits. Whereas adoptive
therapy requires sophisticated infrastructures, checkpoint antibody therapy can be more
easily distributed. Unfortunately, the mechanisms underlying therapeutic resistance to
checkpoint blockade agents remain poorly understood, and the field faces a major gap in
knowledge between our present understanding of mechanisms of tumor immune evasion at
the steady state, and tumor resistance to immunomodulatory therapy. It is likely that
checkpoint blockade fails because constitutive or adaptive tolerance mechanisms
suppressing antigen-presentation and/or T cell homing and function are so powerful in many
tumors that cannot be overcome solely by checkpoint blockade. A major challenge in
addressing these mechanisms relates to the complexity of tumor microenvironment
immunoregulatory systems, where tumor cells and an ever-growing list of tumor-infiltrating
host leukocytes and stromal cells (including blood and lymphatic endothelial cells, and
fibroblasts) can block T cell homing, engraftment or effector function, using diverse but
often overlapping mechanisms. To translate this knowledge towards the development of
rational (and personalized) therapies, one must develop knowledge and tools that allow
integrating these pathways and deciphering their functional order and hierarchies (if any
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exist). For example, at the steady state, it is important to understand whether escape
mechanisms differ among tumors, and if so, whether there are hierarchically dominant
mechanisms, which could be targeted therapeutically first. From the therapeutic standpoint,
it is unclear which of these mechanisms contribute to lack of response to checkpoint
blockade, and how they may interact – when coexisting - to produce therapeutic resistance.
Reversing the argument, it is unclear which of these escape mechanisms can be overcome by
activating lymphocytes through checkpoint blockade alone, and which continue to act as a
barrier to attenuate or abolish the effect of checkpoint blockade. It is likely that such
mechanisms may not have a well-defined hierarchy, but their logic may be organized in
networks. Although many of these resistance mechanisms are pre-existing, others may
emerge in response to tumor adaptation to effective immune attack. Understanding this
complex system requires new methods, including the development of high throughput
experimental models that capture the heterogeneity of tumors among patients, and which
allow systems pharmacology approaches producing large orthogonal datasets, and systems
biology analytical approaches (Network, 2012).
Recognition of the complexity of biological networks has on one hand made it more difficult
to identify appropriate therapeutic choices, but on the other hand, insights from systems
biology suggest a new way of thinking about treatment resistance that may directly lead to
new designs for trials. The tumor microenvironment coopts robust mechanisms of tissue
repair, developed to promote homeostasis following injury, which summon overlapping
cellular and molecular mechanisms promoting immune tolerance, angiogenesis, extracellular
remodeling, and tissue repair. Successful immunotherapy must offer combinatorial strategies
that make it impossible to block T cell responses, either by eliminating an essential, non-
redundant central component, or alternatively, by simultaneously targeting multiple
components that are able to compensate for each other’s activity. Such knowledge can only
be developed effectively with experimental and analytical systems approaches and
innovative adaptive designs in clinical trials.
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Figure 1.
Generation of an anti-tumor T cell response. Dendritic cells acquire tumor antigens from
necrotic or apoptotic tumor cells, and then home to regional lymph nodes. Within the lymph
nodes, DCs activate T cells (and NK cells) and they then traffic to the tumor site. Activated
lymphocytes cross the tumor endothelial barrier, recognize tumor targets, and secrete
cytokines and directly kill tumor targets. This process is under considerable suppression
from the tumors, as they mount challenges to each step that prevents optimal T cell
activation. Within the tumor site, suppressive cells like Tregs and MDSC are recruited by
tumors and actively suppress lymphocytes from killing tumor targets.
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Figure 2.
Tumor endothelium in immune suppression. A, The endothelium is a physical barrier to T
cell trafficking. During the normal inflammatory response, TNFα upregulates adhesion
molecules ICAM and VCAM. While rolling, T cells bind to the adhesion molecules through
LFA-1 and VLA-1, followed by extravasation through the endothelium and home to the site
of inflammation. In the tumor microenvironment, tumor-derived angiogenic growth factors
such as VEGF and ET-1 signal through their cognate receptors on the endothelium and
block the expression of adhesion molecules, preventing T cell infiltration. B, The
endothelium is a direct modulator of immune suppression. Under the influence of tumor-
and stromal-derived factors (e.g., VEGF), the tumor endothelium expresses a number of
immunosuppressive molecules such as TIM-3, IDO, PDL1/2, and PGE2. The expression of
these molecules limit effector T cell activation. Further, the endothelium can also express a
number of genes (e.g., TRAIL) that can directly kill effector T cells as they attempt to
transverse the endothelial barrier.
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Figure 3.
After arrival within the tumor microenvironment, effector T cell functions are suppressed by
a number of mechanisms including interactions with both soluble and cell surface-expressed
mediators.
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